Indication

HER2-positive adenocarcinoma of gastroesophageal junction

HER2-positive adenocarcinoma of the gastroesophageal junction is a distinct histological and molecular subtype of upper gastrointestinal cancer arising from glandular epithelial tissue at the anatomical transition between the distal esophagus and proximal stomach. Read more about HER2-positive adenocarcinoma of gastroesophageal junction

39 drugs 37 manufacturers

Advertisement

Drugs that treat it

Common HER2-positive adenocarcinoma of gastroesophageal junction therapies.

Showing 19–27 of 39 drugs

CAPECITABINE

5 FLUOROPYRIMIDINES·MALIGNANT ESOPHAGEAL NEOPLASM·+7
CAMBER PHARMACE
Filter & compare in the drug finder →Opens the drug finder with HER2-positive adenocarcinoma of gastroesophageal junction preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About HER2-positive adenocarcinoma of gastroesophageal junction.

HER2-positive adenocarcinoma of the gastroesophageal junction is a distinct histological and molecular subtype of upper gastrointestinal cancer arising from glandular epithelial tissue at the anatomical transition between the distal esophagus and proximal stomach.

Pathophysiologically, the tumor is characterized by amplification of the *ERBB2* gene or overexpression of the human epidermal growth factor receptor 2 (HER2) protein, typically confirmed by standard immunohistochemistry (IHC 3+) or in situ hybridization (IHC 2+/ISH+) testing.

This receptor tyrosine kinase overexpression drives unregulated cellular proliferation, invasion, and aggressive tumor biology in affected patients, defining an oncogenic subset that is specifically susceptible to HER2-directed targeted therapies.

Personalize your experience

Follow HER2-positive adenocarcinoma of gastroesophageal junction and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it